News
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...
InvestorsHub on MSN1d
Merck Launches Final-Stage Trial of Dengue Vaccine for ChildrenMerck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric ...
Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
The stock's fall snapped a three-day winning streak.
Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback